vs

Side-by-side financial comparison of ADAMAS TRUST, INC. (ADAM) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

ADAMAS TRUST, INC. is the larger business by last-quarter revenue ($43.2M vs $27.6M, roughly 1.6× Zymeworks Inc.). ADAMAS TRUST, INC. runs the higher net margin — 124.0% vs -71.0%, a 195.0% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 61.6%). ADAMAS TRUST, INC. produced more free cash flow last quarter ($125.9M vs $-31.8M).

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

ADAM vs ZYME — Head-to-Head

Bigger by revenue
ADAM
ADAM
1.6× larger
ADAM
$43.2M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+11.0% gap
ZYME
72.6%
61.6%
ADAM
Higher net margin
ADAM
ADAM
195.0% more per $
ADAM
124.0%
-71.0%
ZYME
More free cash flow
ADAM
ADAM
$157.7M more FCF
ADAM
$125.9M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ADAM
ADAM
ZYME
ZYME
Revenue
$43.2M
$27.6M
Net Profit
$53.5M
$-19.6M
Gross Margin
Operating Margin
-80.1%
Net Margin
124.0%
-71.0%
Revenue YoY
61.6%
72.6%
Net Profit YoY
270.5%
34.3%
EPS (diluted)
$0.45
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADAM
ADAM
ZYME
ZYME
Q4 25
$43.2M
Q3 25
$36.6M
$27.6M
Q2 25
$36.4M
$48.7M
Q1 25
$33.1M
$27.1M
Q4 24
$26.7M
$31.0M
Q3 24
$20.2M
$16.0M
Q2 24
$19.0M
$19.2M
Q1 24
$17.9M
$10.0M
Net Profit
ADAM
ADAM
ZYME
ZYME
Q4 25
$53.5M
Q3 25
$44.8M
$-19.6M
Q2 25
$8.5M
$2.3M
Q1 25
$42.2M
$-22.6M
Q4 24
$-31.4M
$-23.5M
Q3 24
$42.8M
$-29.9M
Q2 24
$-15.6M
$-37.7M
Q1 24
$-57.9M
$-31.7M
Operating Margin
ADAM
ADAM
ZYME
ZYME
Q4 25
Q3 25
-80.1%
Q2 25
11.7%
-1.4%
Q1 25
-94.5%
Q4 24
-119.0%
-71.6%
Q3 24
-213.8%
Q2 24
-124.7%
-222.9%
Q1 24
-448.8%
-376.9%
Net Margin
ADAM
ADAM
ZYME
ZYME
Q4 25
124.0%
Q3 25
122.5%
-71.0%
Q2 25
23.4%
4.8%
Q1 25
127.4%
-83.5%
Q4 24
-117.5%
-75.8%
Q3 24
211.7%
-186.6%
Q2 24
-81.9%
-195.8%
Q1 24
-324.1%
-315.6%
EPS (diluted)
ADAM
ADAM
ZYME
ZYME
Q4 25
$0.45
Q3 25
$0.36
$-0.26
Q2 25
$-0.04
$0.03
Q1 25
$0.33
$-0.30
Q4 24
$-0.46
$-0.32
Q3 24
$0.36
$-0.39
Q2 24
$-0.29
$-0.49
Q1 24
$-0.75
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADAM
ADAM
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$210.3M
$64.8M
Total DebtLower is stronger
$735.8M
Stockholders' EquityBook value
$1.4B
$320.1M
Total Assets
$12.6B
$397.3M
Debt / EquityLower = less leverage
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADAM
ADAM
ZYME
ZYME
Q4 25
$210.3M
Q3 25
$185.3M
$64.8M
Q2 25
$160.4M
$98.3M
Q1 25
$177.1M
$76.2M
Q4 24
$167.4M
$66.1M
Q3 24
$195.1M
$122.4M
Q2 24
$235.5M
$71.0M
Q1 24
$226.9M
$114.8M
Total Debt
ADAM
ADAM
ZYME
ZYME
Q4 25
$735.8M
Q3 25
$766.6M
Q2 25
$653.0M
Q1 25
$654.4M
Q4 24
$573.2M
Q3 24
$699.4M
Q2 24
$800.7M
Q1 24
$1.0B
Stockholders' Equity
ADAM
ADAM
ZYME
ZYME
Q4 25
$1.4B
Q3 25
$1.4B
$320.1M
Q2 25
$1.4B
$334.5M
Q1 25
$1.4B
$325.0M
Q4 24
$1.4B
$338.8M
Q3 24
$1.4B
$367.0M
Q2 24
$1.4B
$406.2M
Q1 24
$1.5B
$438.0M
Total Assets
ADAM
ADAM
ZYME
ZYME
Q4 25
$12.6B
Q3 25
$12.4B
$397.3M
Q2 25
$10.6B
$408.4M
Q1 25
$10.0B
$425.5M
Q4 24
$9.2B
$463.1M
Q3 24
$8.9B
$487.2M
Q2 24
$8.2B
$515.6M
Q1 24
$7.4B
$553.8M
Debt / Equity
ADAM
ADAM
ZYME
ZYME
Q4 25
0.52×
Q3 25
0.55×
Q2 25
0.47×
Q1 25
0.47×
Q4 24
0.41×
Q3 24
0.48×
Q2 24
0.56×
Q1 24
0.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADAM
ADAM
ZYME
ZYME
Operating Cash FlowLast quarter
$134.0M
$-31.4M
Free Cash FlowOCF − Capex
$125.9M
$-31.8M
FCF MarginFCF / Revenue
291.6%
-115.2%
Capex IntensityCapex / Revenue
18.9%
1.5%
Cash ConversionOCF / Net Profit
2.50×
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADAM
ADAM
ZYME
ZYME
Q4 25
$134.0M
Q3 25
$6.9M
$-31.4M
Q2 25
$39.2M
$12.1M
Q1 25
$25.8M
$-3.4M
Q4 24
$14.1M
$-41.5M
Q3 24
$-922.0K
$-5.9M
Q2 24
$-993.0K
$-25.0M
Q1 24
$-13.1M
$-37.7M
Free Cash Flow
ADAM
ADAM
ZYME
ZYME
Q4 25
$125.9M
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-10.6M
$-41.8M
Q3 24
$-8.6M
$-6.8M
Q2 24
$-8.6M
$-25.6M
Q1 24
$-19.1M
$-37.9M
FCF Margin
ADAM
ADAM
ZYME
ZYME
Q4 25
291.6%
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-39.6%
-134.8%
Q3 24
-42.3%
-42.4%
Q2 24
-44.9%
-133.0%
Q1 24
-107.0%
-377.5%
Capex Intensity
ADAM
ADAM
ZYME
ZYME
Q4 25
18.9%
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
92.3%
1.0%
Q3 24
37.7%
5.6%
Q2 24
39.7%
3.1%
Q1 24
33.5%
1.8%
Cash Conversion
ADAM
ADAM
ZYME
ZYME
Q4 25
2.50×
Q3 25
0.15×
Q2 25
4.59×
5.21×
Q1 25
0.61×
Q4 24
Q3 24
-0.02×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADAM
ADAM

Other$19.6M45%
Constructive Loans LLC$14.4M33%
Multifamily$9.1M21%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons